1. Home
  2. PYPL vs ARGX Comparison

PYPL vs ARGX Comparison

Compare PYPL & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PayPal Holdings Inc.

PYPL

PayPal Holdings Inc.

HOLD

Current Price

$53.06

Market Cap

56.7B

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$848.64

Market Cap

50.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PYPL
ARGX
Founded
1998
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.7B
50.4B
IPO Year
2002
2017

Fundamental Metrics

Financial Performance
Metric
PYPL
ARGX
Price
$53.06
$848.64
Analyst Decision
Hold
Strong Buy
Analyst Count
30
19
Target Price
$76.27
$979.22
AVG Volume (30 Days)
14.9M
402.2K
Earning Date
02-03-2026
02-26-2026
Dividend Yield
1.04%
N/A
EPS Growth
18.59
N/A
EPS
4.98
23.27
Revenue
$32,862,000,000.00
$3,683,281,000.00
Revenue This Year
$6.79
$91.44
Revenue Next Year
$5.69
$36.90
P/E Ratio
$10.86
$33.83
Revenue Growth
4.47
92.98
52 Week Low
$53.65
$510.06
52 Week High
$90.93
$934.62

Technical Indicators

Market Signals
Indicator
PYPL
ARGX
Relative Strength Index (RSI) 28.09 54.91
Support Level $56.41 $810.52
Resistance Level $57.12 $881.89
Average True Range (ATR) 1.17 21.38
MACD -0.20 7.50
Stochastic Oscillator 8.29 70.10

Price Performance

Historical Comparison
PYPL
ARGX

About PYPL PayPal Holdings Inc.

PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 434 million active accounts at the end of 2024. The company also owns Venmo, a person-to-person payment platform.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: